Jason Li

Jason Li began their work experience as a resident surgeon specializing in neurosurgery at Huashan Hospital, Fudan University in July 2017. Jason continued in this role until August 2018. In July 2018, they joined Dizal Pharmaceutical as a medical scientist. The company, a spin-off from AstraZeneca, focuses on drug development in oncology and autoimmune diseases. Jason's roles at Dizal have progressed from senior medical scientist to clinical research physician.

Jason Li received their Bachelor of Medicine, Bachelor of Surgery (MBBS) degree in Clinical Medicine from Fudan University in 2012. Jason then pursued further education at Fudan University, where they earned their Doctor of Medicine (MD) degree in Neurosurgery in 2017.